关于神经血管与年龄相关的黄斑变性长期观察数据:一项10年后续研究
Feyza Cukurova1, Belgin Izgi2, Zafer Cebeci2
1Department of Ophthalmology, Istanbul University Istanbul Medical Faculty, 34093, Istanbul, Turkey. feyzacukurova143@gmail.com.
International ophthalmology
|July 1, 2025
概括
使用血管内皮生长因子 (VEGF) 抑制剂治疗的神经血管年龄相关黄斑变性 (nAMD) 患者的初始视力敏度维持了10年. 及时,定期治疗可以在nAMD中实现长期的功能视力.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 医疗视网膜 医学视网膜
背景情况:
- 神经血管与年龄相关的黄斑变性 (nAMD) 是导致视力丧失的主要原因.
- 血管内皮生长因子 (VEGF) 抑制剂是对nAMD的标准治疗.
- 对nAMD的VEGF抑制剂治疗的长期真实数据至关重要.
研究的目的:
- 为了评估用VEGF抑制剂治疗的nAMD眼睛的10年现实生活结果.
- 评估最佳校正视敏度 (BCVA) 和解剖结果的变化.
- 确定影响长期视觉结果的因素在nAMD.
主要方法:
- 追溯分析102个曾经没有使用过抗VEGF的nAMD眼睛,随访时间至少7年.
- 主要结局:10年后的BCVA变化.
- 二次结果:解剖学变化,注射频率和检查率.
主要成果:
- 平均随访时间约为10年 (116个月).
- 最初的BCVA在第一年有所改善,但到第10年逐渐下降.
- 影响结果的重要变量包括年龄,基线BCVA,先前的光动力学治疗和视网膜出血.
结论:
- 患有nAMD的眼睛在接受VEGF抑制剂治疗后,在10年内维持了最初的BCVA.
- 在nAMD中,定期及时治疗是实现长期功能视力的关键.
- 现实世界的数据支持VEGF抑制剂在nAMD管理中的持续有效性.
更多相关视频
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.2K
10:24Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
10.3K
相关概念视频
01:25Glaucoma: Overview
782
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
782
01:27Open Angle Glaucoma: Treatment
586
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
586